Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia. The second presentation is on preclinical data for Nutcracker’s mRNA drug candidate for prostate cancer, NTX-470. This therapy is designed to target prostate cancer antigens with mRNA-encoded, multi-specific T cell engagers with a strong anti-tumor effect and low toxicity.
Poster Presentations at AACR 2024
Title: NTX-470, a novel multispecific T cell engager expressed from mRNA targets PSMA and STEAP1 prostate cancer antigens to generate enhanced functional activity
Abstract Number: 6725
Session Title: Targeted Immune Cell Engagers
Session Date and Time: April 10, 2024, 9:00 a.m. to 12:30 p.m.
Lead Author: Chris Rae
Title: Enhanced membrane stability of mRNA nanoparticle derived TNFSF14 results in superior T- cell and NK cell stimulation
Abstract Number: 6536
Session Title: Tumor Microenvironment and Cancer Immunity
Session Date and Time: April 9, 2024, 1:30 p.m. to 5:00 p.m.
Lead Author: Adrienne Sallets
The 2024 AACR Annual Meeting takes place in San Diego from April 5-10. Full abstracts are available on the AACR Online Program Planner. More information about the conference can be found on AACR’s website.
About Nutcracker Therapeutics, Inc.
Nutcracker Therapeutics, Inc., is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker’s technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.
For more information, visit www.nutcrackerx.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312128104/en/
Contacts
Maggie Williard
HDMZ
Nutcrackerpr@hdmz.com
